126 related articles for article (PubMed ID: 18555943)
1. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.
Zilberberg MD; Kothari S; Shorr AF
Crit Care; 2009; 13(3):R94. PubMed ID: 19545361
[TBL] [Abstract][Full Text] [Related]
3. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.
Seibel NL; Schwartz C; Arrieta A; Flynn P; Shad A; Albano E; Keirns J; Lau WM; Facklam DP; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2005 Aug; 49(8):3317-24. PubMed ID: 16048942
[TBL] [Abstract][Full Text] [Related]
5. Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia.
Yu DT; Seger DL; Peterson JF; Kumar RN; Bates DW
BMC Infect Dis; 2006 Dec; 6():173. PubMed ID: 17147804
[TBL] [Abstract][Full Text] [Related]
6. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.
Dvorak CC; Fisher BT; Sung L; Steinbach WJ; Nieder M; Alexander S; Zaoutis TE
Pediatr Blood Cancer; 2012 Jul; 59(1):21-6. PubMed ID: 22102607
[TBL] [Abstract][Full Text] [Related]
7. Plasma Concentration of Antifungal Agent Micafungin for Pediatric Living Donor Liver Transplantation.
Ueno T; Takase K; Deguchi K; Nomura M; Watanabe M; Kamiyama M; Tazuke Y; Kimura T; Okuyama H
Transplant Proc; 2024 Apr; 56(3):602-604. PubMed ID: 38326203
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin - case study and brief literature review.
Barańska M; Kroll-Balcerzak R; Gil L; Rupa-Matysek J; Komarnicki M
Cent Eur J Immunol; 2017; 42(1):111-115. PubMed ID: 28680340
[TBL] [Abstract][Full Text] [Related]
9. Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia.
Theodore DA; Henneman AD; Loo A; Shields RK; Eschenauer G; Sobieszczyk ME; Kubin CJ
J Antimicrob Chemother; 2024 Jun; ():. PubMed ID: 38831614
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole and levofloxacin prophylaxis are ineffective strategies for preventing infections in acute myeloid leukemia patients undergoing chemotherapy.
Soldi LR; Silva MJB
Cancer Epidemiol; 2024 May; 91():102593. PubMed ID: 38815484
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
12. The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: a systematic review and meta-analysis.
Soldi LR; Coelho YNB; Paranhos LR; Silva MJB
Clin Exp Med; 2023 Nov; 23(7):3231-3249. PubMed ID: 37058186
[TBL] [Abstract][Full Text] [Related]
13. Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies.
Rubinstein SM; Culos KA; Savani B; Satyanarayana G
Bone Marrow Transplant; 2018 Feb; 53(2):123-128. PubMed ID: 29058698
[TBL] [Abstract][Full Text] [Related]
14. Micafungin: an evidence-based review of its place in therapy.
de la Torre P; Reboli AC
Core Evid; 2014; 9():27-39. PubMed ID: 24596542
[TBL] [Abstract][Full Text] [Related]
15. Oral complications and management strategies for patients undergoing cancer therapy.
Wong HM
ScientificWorldJournal; 2014; 2014():581795. PubMed ID: 24511293
[TBL] [Abstract][Full Text] [Related]
16. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
[TBL] [Abstract][Full Text] [Related]
17. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.
Ethier MC; Science M; Beyene J; Briel M; Lehrnbecher T; Sung L
Br J Cancer; 2012 May; 106(10):1626-37. PubMed ID: 22568999
[TBL] [Abstract][Full Text] [Related]
18. Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.
Pechlivanoglou P; De Vries R; Daenen SM; Postma MJ
Pharmacoeconomics; 2011 Sep; 29(9):737-51. PubMed ID: 21657801
[TBL] [Abstract][Full Text] [Related]
19. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
Wilke M
Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study.
Kim YJ; Sung KW; Hwang HS; Jung SH; Kim JY; Cho EJ; Lim SJ; Choi YB; Cheuh HW; Lee SH; Yoo KH; Koo HH
Yonsei Med J; 2011 Mar; 52(2):293-300. PubMed ID: 21319349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
